/PRNewswire/ Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed.
A new study presented during the Transcatheter Cardiovascular Therapeutics conference, TCT 2023, revealed inequities in access to mechanical circulatory support in United States’ patients with cardiogenic shock. The findings, simultaneously published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI), revealed stark disparities, particularly among black patients, that further highlight systemic inequities in access to lifesaving therapies.
/PRNewswire/ Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly.
The Society of Thoracic Surgeons and the European Association for Cardiothoracic Surgeons have issued a joint statement in response to the new research on aortic valve replacement in low-risk patients announced during the Transcatheter Cardiovascular Therapeutics Conference, TCT 2023, and recently published in The Annals of Thoracic Surgery.